Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03611075 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)

A Phase 1 study of Autism Spectrum Disorder, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
144
Enrollment target
18
Study locations

NCT03611075: Completed Phase 1 study of Autism Spectrum Disorder, sponsored by Hoffmann-La Roche.

NCT03611075 is a Phase 1 study of Autism Spectrum Disorder that has completed, run by Hoffmann-La Roche. The registered enrollment target is 144 participants, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target. The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03611075, a Phase 1 study of Autism Spectrum Disorder, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
144 participants
Enrollment target
18
Study locations

Study Summary

This is a non-drug study seeking to characterize different scales to measure repetitive and restrictive behaviors in different ASD sub-populations over time. This study will also explore the use of digital biomarkers.

Primary Outcome

The CY-BOCS-ASD is where the interviewer asks the parent/caregiver about past and present repetitive behaviors, guided by the revised repetitive behavior checklist with a list of 25 behaviors, classified into the following categories: Hoarding/ritualistic behavior, Sensorymotor and arranging, Insistence on routines /Self-injurious behaviors, Stereotypy and Restricted interests. This checklist was expanded to include repetitive behaviors commonly seen in children with ASD. A target symptom list c

Conditions Studied

Interventions

  • OTHER No Intervention

Study Locations (18)

Texas

  • BioBehavioral Research of Austin, PC - Austin
  • Red Oak Psychiatry Associates, PA - Houston
  • Road Runner Research Ltd - San Antonio

California

  • PCSD Feighner Research - San Diego
  • Stanford University School of Medicine - Stanford

New York

  • Nathan S. Kline Institute for Psychiatric Research - Orangeburg
  • Albert Einstein College of Medicine - The Bronx

Washington

  • Northwest Clinical Research Center - ClinEdge - PPDS - Bellevue
  • Seattle Children's Hospital - PIN; Investigational Drug Services - Seattle

Other

  • Gartnavel Royal Hospital; Mental Health & Wellbeing - Glasgow
  • Kings College London - London

Alabama

  • Harmonex Neuroscience Research - Dothan

Arizona

  • Southwest Autism Research and Resource Center - Phoenix

Florida

  • Clinical Neuroscience Solutions Inc; Jacksonville Clinic - Jacksonville

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2018-08-13
Est. Completion 2020-05-21
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the finished NCT03611075 record still lists

NCT03611075 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target.

The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.

NCT03611075 lists 18 locations in 12 states (Texas, California, New York).

Frequently Asked Questions

What is clinical trial NCT03611075 about?

NCT03611075 is a clinical study titled "A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)". This is a non-drug study seeking to characterize different scales to measure repetitive and restrictive behaviors in different ASD sub-populations over time. This study will also explore the use of digital biomarkers.

What is the current status of trial NCT03611075?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2018-08-13. Estimated completion is 2020-05-21.

What conditions does trial NCT03611075 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder.

What interventions are being tested in trial NCT03611075?

The interventions under investigation include: No Intervention (OTHER).

Who is sponsoring clinical trial NCT03611075?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03611075 being conducted?

This trial has 18 study locations across Alabama, Arizona, California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03611075's enrollment target sits among peer trials

144 56th of 224 higher than 166 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03611075, the US trial registry maintained by the National Library of Medicine. NCT03611075 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.